PF-06439535 (a Bevacizumab Biosimilar) Compared with Reference Bevacizumab (Avastin®), Both Plus Paclitaxel and Carboplatin, as First-Line Treatment for Advanced Non-Squamous Non-Small-Cell Lung Cancer: A Randomized, Double-Blind Study

Niels Reinmuth1 · Maciej Bryl2 · Igor Bondarenko3 · Kostas Syrigos4 · Vladimir Vladimirov2 · Manuela Zereu6 · Angel H. Bair7 · Fiona Hilton7 · Katherine Liau7 · Kazuo Kasahara8

Published online: 23 July 2019 © The Author(s) 2019

Abstract
Background PF-06439535 is a bevacizumab biosimilar. We aimed to compare the efficacy and safety of PF-06439535 with that of reference bevacizumab (Avastin®) sourced from the EU (bevacizumab-EU), each with paclitaxel and carboplatin, in the first-line treatment of advanced non-squamous non-small-cell lung cancer (NSCLC).

Methods In this double-blind, parallel-group study, we recruited patients from 159 centers in 27 countries. Participants were randomized 1:1 to receive PF-06439535 plus paclitaxel and carboplatin or bevacizumab-EU plus paclitaxel and carboplatin on day 1 of each 21-day cycle for 4–6 cycles, followed by blinded monotherapy with PF-06439535 or bevacizumab-EU until disease progression, unacceptable toxicity, withdrawal of consent, or the end of the study. Randomization was stratified by region, sex, and smoking history. The primary endpoint was objective response rate (ORR) in accordance with RECIST 1.1, based on responses achieved by week 19 and confirmed by week 25.

Results Between 21 May 2015 and 14 November 2016, 719 patients were randomized to the PF-06439535 group (n = 358) or the bevacizumab-EU group (n = 361). As of data cutoff for analysis of the primary endpoint (8 May 2017), 45.3% (95% confidence interval [CI] 40.01–50.57) of patients in the PF-06439535 group and 44.6% (95% CI 39.40–49.89) of patients in the bevacizumab-EU group achieved an objective response by week 19 that was confirmed by week 25. The unstratified ORR risk ratio was 1.015 (95% CI 0.863–1.193; 90% CI 0.886–1.163), and the unstratified ORR risk difference was 0.653% (95% CI −6.608 to 7.908); all three CIs fell within pre-specified equivalence margins. Using final data after study completion (22 December 2017), no notable differences in progression-free survival or overall survival were observed between the groups. The most frequently reported grade 3 or higher treatment-emergent adverse events were hypertension, neutropenia, and anemia. There were no clinically meaningful differences in safety, pharmacokinetics, or immunogenicity across treatment groups.

Conclusion Among patients with advanced non-squamous NSCLC, PF-06439535 demonstrated similarity to bevacizumab-EU in terms of efficacy. Safety profiles for the two treatments were comparable.

Trial Registration ClinicalTrials.gov, NCT02364999.

Funding Pfizer.

1 Introduction

Vascular endothelial growth factor (VEGF) is a key regulator of tumor angiogenesis [1]. Elevated expression of VEGF is observed in many cancers and has been associated with poorer prognosis, including an increased likelihood of cancer recurrence, tumor metastasis, and death [2–4]. Bevacizumab (Avastin®) is a recombinant humanized monoclonal antibody that binds to and inhibits the biological activity of VEGF by interrupting its interaction with endothelial cell-surface receptors [5, 6].

Bevacizumab was licensed by the US Food and Drug Administration (FDA) in 2004 for the first-line treatment of metastatic colorectal cancer in combination with chemotherapy [5]. Authorization in the European Union (EU) followed in 2005 [6]. Since that time, bevacizumab has
been approved for the treatment of several additional cancers, including non-squamous non-small-cell lung cancer (NSCLC), recurrent glioblastoma, metastatic renal cell carcinoma, cervical cancer, and ovarian cancer [5, 6]. Across tumor types, randomized controlled trials have demonstrated that bevacizumab plus chemotherapy is associated with benefits such as improved overall survival (OS) and progression-free survival (PFS) relative to chemotherapy alone [7–9], and bevacizumab continues to have a prominent position in cancer treatment algorithms [10, 11]. Despite such benefits, however, patient access to bevacizumab may be limited, owing to factors such as lack of reimbursement and high out-of-pocket costs [12].

Biosimilars are biological products that are highly similar to a licensed reference biologic, with no clinically meaningful differences in quality characteristics, biological activity, safety, or efficacy [13–15]. The introduction of biosimilars has been associated with cost savings [16], and the American Society of Clinical Oncology and the European Society for Medical Oncology have highlighted the importance of biosimilars in enhancing patient access to anticancer therapies and supporting the sustainability of cancer care [17, 18]. Biosimilars are developed in a stepwise process of head-to-head comparison with the reference product in analytical, nonclinical, and clinical studies, with biosimilarity determined based on the totality of evidence [13–15].

PF-06439535 (Zirabev™) is a bevacizumab biosimilar [19]. Comprehensive comparative analytical studies have established that PF-06439535 has an identical amino acid sequence to reference bevacizumab (Avastin®) sourced from the EU (bevacizumab-EU) and the US (bevacizumab-US), and that it exhibits functional similarity to these reference products [20]. Nonclinical in vivo studies have provided evidence of similarity between PF-06439535 and bevacizumab-EU in toxicity, toxicokinetics, and immunogenicity [20]. Furthermore, a comparative, single-dose study in healthy male volunteers demonstrated the pharmacokinetic (PK) similarity of PF-06439535, bevacizumab-EU, and bevacizumab-US, with no marked differences observed in safety or immunogenicity [21].

We conducted the current study (B7391003) to compare the efficacy and safety of PF-06439535 plus paclitaxel and carboplatin with that of bevacizumab-EU plus paclitaxel and carboplatin in the first-line treatment of advanced non-squamous NSCLC. Our primary objective was to assess whether PF-06439535 demonstrated similarity to bevacizumab-EU, based on the confirmed objective response rate (ORR) in each treatment group.

2 Methods

2.1 Study Design and Patients

This was a multinational, double-blind, randomized, parallel-group study registered at ClinicalTrials.gov (NCT02364999) and EudraCT (2014-003878-16). Patients were randomized at 159 centers in 27 countries (see Electronic Supplementary Material [ESM], Table S1). Adult patients were eligible for inclusion if they had histologically or cytologically confirmed, predominantly non-squamous, newly diagnosed Stage IIIB or IV NSCLC (according to lung cancer staging criteria of 2010 [22, 23]) or recurrent NSCLC. For patients with recurrent disease, at least 6 months must have elapsed since completing adjuvant or neoadjuvant treatment. Additionally, patients had at least one measurable lesion per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) [24], an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and were eligible to receive study treatment of bevacizumab, paclitaxel, and carboplatin based on the local standard of care for the treatment of advanced or metastatic non-squamous NSCLC. Key exclusion criteria included known central nervous system metastases (treated and stable brain metastases were allowed); known sensitizing EGFR mutations or EML4–ALK translocations (patients with unknown status were permitted to enroll); prior systemic therapy for NSCLC (prior neoadjuvant or adjuvant therapy was allowed if surgical resection for primary disease was performed); and prior treatment with immunotherapy or bevacizumab. Full eligibility criteria can be found in the ESM.

The original protocol (dated 4 November 2014) was amended three times; details of the changes can be found in
the final version of the protocol (dated 10 June 2016), which is available at ClinicalTrials.gov.

2.2 Randomization and Blinding

Patients were enrolled by study investigators and randomized in a 1:1 ratio to receive either PF-06439535 plus paclitaxel and carboplatin or bevacizumab-EU plus paclitaxel and carboplatin for 4–6 cycles, followed by blinded monotherapy with PF-06439535 or bevacizumab-EU as previously assigned (ESM, Fig. S1). The randomization schedule was computer-generated by the sponsor and included the stratification variables of region (location of the drug depot supplying the site), sex (male/female), and smoking history (never/ever). The schedule was concealed from the sponsor’s personnel directly involved in study conduct and was implemented by the study sites using an interactive web response system.

Treatment assignments were blinded to patients, investigators, and the sponsor’s study team. Limited members of the sponsor’s study team were unblinded at the time of the primary efficacy analysis. Site personnel and patients remained blinded until the completion of the study. PF-06439535 and bevacizumab-EU were provided by the sponsor as blinded supplies in which the external packaging for each vial appeared identical and was identified with a unique container number. Paclitaxel and carboplatin were branded products or generic equivalents available in the local region. Use of nab-paclitaxel in place of paclitaxel was not permitted.

2.3 Treatments

On treatment days when PF-06439535 or bevacizumab-EU was administered in combination with chemotherapy, the order of administration was paclitaxel, carboplatin, and PF-06439535 or bevacizumab-EU. Treatments were administered by intravenous infusion on day 1 of each 21-day cycle. Paclitaxel was administered at an initial dose of 200 mg/m², carboplatin at an initial dose targeting an area under the concentration versus time curve of 6.0 mg/mL·min, and PF-06439535 or bevacizumab-EU at an initial dose of 15 mg/kg. Paclitaxel and carboplatin dose reductions were allowed for toxicity. No dose reductions were planned for PF-06439535 or bevacizumab-EU, but if deemed necessary the investigator could decrease the dose to 7.5 mg/kg after discussion with the sponsor. Patients were pre-medicated before paclitaxel administration in order to prevent severe hypersensitivity reaction.

After chemotherapy had been discontinued, PF-06439535 or bevacizumab-EU monotherapy could be administered before paclitaxel administration in order to prevent severe hypersensitivity reaction.

After chemotherapy had been discontinued, PF-06439535 or bevacizumab-EU monotherapy could be administered until disease progression (defined per RECIST 1.1), unacceptable toxicity, discretion of the investigator, death, withdrawal of consent, or the end of the study, whichever came first. The dose and regimen for PF-06439535 and bevacizumab-EU were chosen to be consistent with the product labeling of bevacizumab-EU. The chemotherapy given and the regimens used were considered standard of care.

2.4 Endpoints and Assessments

The primary endpoint was ORR, defined as the percentage of patients within each treatment group who achieved a best overall response (BOR) of complete response (CR) or partial response (PR) by week 19 in accordance with RECIST 1.1, which was subsequently confirmed on a follow-up tumor assessment by week 25. BOR was derived by the sponsor based on tumor measurements reported by the investigator. This endpoint was considered sufficiently sensitive to detect differences in efficacy between PF-06439535 and bevacizumab-EU. The choice of primary endpoint and the use of investigator-reported tumor measurements were agreed with regulatory authorities.

Secondary efficacy endpoints were duration of response (DOR), 1-year PFS rate, and 1-year OS rate from randomization. DOR was calculated only for the subgroup of patients with an objective response achieved by week 19 and confirmed by week 25. Additional secondary endpoints included safety, peak and trough PF-06439535 and bevacizumab-EU concentrations at selected cycles up to 1 year from randomization, and incidence of anti-drug antibodies (ADAs; including neutralizing antibodies [NAbs]) up to 1 year from randomization.

Tumor assessments included computed tomography (CT) or magnetic resonance imaging (MRI) scans of the head, chest, abdomen (including adrenals), and other disease sites such as the pelvis if clinically indicated. CT scans were performed with contrast media unless contraindicated for medical reasons. MRI was only used when considered more appropriate than CT or when there was a contraindication for use of CT with contrast. For a given patient, the same method of tumor assessment was used throughout the trial. CT or MRI assessments were performed every 6 weeks (± 7 days) until week 25 (based on date of randomization). After week 25, assessments were performed every 9 weeks (± 7 days) until 1 year from randomization. Responses were required to be confirmed by a second set of scans obtained 6 weeks (± 7 days) later in accordance with RECIST 1.1. Additionally, brain scans were performed as clinically indicated and at the time of a confirmatory scan for CR/PR. Patients who continued to receive study treatment after 1 year had tumor assessments performed according to local standard of care.

Blood samples for assessment of immunogenicity were collected pre-dose at specified study cycles and analyzed for the presence or absence of ADAs (anti-bevacizumab or

△ Adis
anti-PF-06439535 antibodies). A single, sensitive, specific, and semi-quantitative electrochemiluminescent immunoassay was used. The ADA assay had been validated and used biotinylated and ruthenium-labeled PF-06439535 as reagents. Analysis of ADA samples followed a tiered approach of screening, confirmation, and titer determination. Only those samples confirmed positive for ADAs were further tested for NAbs. The NAb analysis was conducted using a single, validated, quasi-quantitative enzyme-linked immunosorbent assay (ELISA) that utilized PF-06439535 as a reagent. Analysis of NAB samples followed a tiered approach of screening and titer determination.

Drug concentrations of PF-06439535 and bevacizumab-EU were determined using serum samples collected at pre-specified time points. Samples were collected pre-dose; in addition, post-dose samples were collected 1 h (± 0.5 h) after the end of infusion on cycle 1, day 1 and cycle 5, day 1. Concentrations were determined using a validated, sensitive, and specific ELISA. Immunogenicity and PK analyses were carried out at QPS, LLC (Newark, DE, USA).

Safety was characterized by the type, incidence, severity, timing, seriousness, and relationship to study therapy of adverse events (AEs), including cardiotoxicity and infusion-related reactions, and laboratory abnormalities. Other safety evaluations included physical examinations, vital signs, and 12-lead electrocardiogram monitoring. The investigator obtained and recorded all observed or volunteered AEs, the severity of the events (based on Common Terminology Criteria for Adverse Events version 4.03), and his or her opinion of the relationship to study treatment. Treatment-emergent AEs (TEAEs) were those that occurred after the beginning of study treatment, or any pre-existing AE that worsened after the beginning of study treatment. AEs of special interest were arterial thromboembolic events, bleeding/hemorrhage (including pulmonary hemorrhage), cardiac disorders, congestive heart failure, hypertension (only grade 3 or higher), proteinuria or nephrotic syndrome, venous thromboembolic events, gastrointestinal perforations, and wound-healing complications.

After discontinuation from treatment, survival status was collected by telephone contact every 2 months (± 14 days) until death or 1 year from patient randomization. The study was considered complete when the last available patient completed up to 1 year from randomization plus a 28-day follow-up period.

2.5 Statistical Analyses

The primary efficacy analysis for the primary endpoint was based on the Miettinen and Nurminen method [25] without stratification variables and was carried out in the intent-to-treat (ITT) population, defined as all patients who were randomized to study treatment. The estimated ORR risk ratio and ORR risk difference between the PF-06439535 and bevacizumab-EU groups were computed, along with asymptotic two-sided 95% and 90% confidence intervals (CIs). Equivalence was determined based on the following criteria agreed with regulatory authorities. For the FDA, equivalence was considered established if the 90% CI of the ORR risk ratio fell within the margin of 0.73–1.37. For Japan’s Pharmaceuticals and Medical Devices Agency (PMDA), equivalence was considered established if the 95% CI of the ORR risk ratio fell within the margin of 0.729–1.371. Finally, for the European Medicines Agency (EMA), equivalence was considered established if the 95% CI of the ORR risk difference fell within the margin of −13% to 13%.

The equivalence margins above were derived based on meta-analysis of three randomized studies of reference bevacizumab plus paclitaxel and carboplatin versus paclitaxel and carboplatin alone in patients with NSCLC [8, 26, 27]. The ORR for reference bevacizumab plus chemotherapy was estimated to be approximately 40%, and the ORR for chemotherapy alone was estimated to be 21%. The ORR risk ratio for bevacizumab plus chemotherapy versus chemotherapy alone was 2.17 (95% CI 1.74–2.70). The margin of 0.73–1.37 in the current study maintained 43% of the effect size estimated from the historical ORR data using a log scale, and approximately 50% using a linear scale. Assuming an ORR of 38% in both treatment arms, a sample of 656 patients (328 per treatment arm) would provide approximately 85% power for achieving equivalence according to the FDA criteria above. Considering a possible ~7.5% attrition rate for patients reaching evaluation for ORR, a total sample of approximately 710 patients (355 per treatment arm) was to be randomized. Using the EMA and PMDA equivalence criteria, and again assuming an ORR of 38%, the planned sample size would provide power of approximately 86% and 74%, respectively.

As a sensitivity analysis, the Miettinen and Nurminen method [25] was also conducted without stratification variables using the per-protocol (PP) population, defined as all patients who were randomized and received PF-06439535 or bevacizumab-EU as planned and had no major protocol deviations. The list of patients not included in the PP population and the reasons for exclusion were determined prior to unblinding for the primary efficacy analysis. As secondary analyses in both the ITT and PP populations, the Miettinen and Nurminen method [25] was repeated with additional stratification variables (region, sex, and smoking history) to assess whether these would affect the ORR risk ratio or risk difference.

Time-to-event endpoints were assessed using the Kaplan–Meier method. A Cox proportional hazard model was used to estimate hazard ratios (HRs); the model included treatment and the covariates of region, sex, and smoking history. The two treatment groups were compared using a
2-sided log-rank test stratified by region, sex, and smoking history.

For the ORR endpoint, if a patient had a missing tumor outcome across all visits or had non-evaluable BOR per RECIST 1.1, he or she was considered a non-responder and was included in the denominator, but not the numerator. For the time-to-event endpoints, missing data were censored.

The safety population, defined as all patients who were randomized and received at least one dose of study treatment, was used for safety and immunogenicity analyses. AEs were summarized by body system and preferred term according to the Medical Dictionary for Regulatory Activities (version 20.1) classification system. The percentage of patients with positive ADA and NAb results was summarized for each treatment and each visit. Patients in the PP population who had at least one drug concentration measurement post-administration of treatment were included in the PK analysis. The drug concentration–time data were summarized by descriptive statistics according to treatment.

The primary efficacy analysis for statistical equivalence was performed when all patients had completed the week 25 visit to support the primary endpoint analysis or had discontinued from the disease evaluation period earlier. All other analyses presented herein are based on final data after study completion. All statistical analyses were conducted as specified in the statistical analysis plan, which can be accessed at ClinicalTrials.gov.

3 Results

3.1 Patient Baseline Characteristics and Disposition

Patients were randomized between 21 May 2015 and 14 November 2016. The data cutoff date for analysis of the primary efficacy endpoint was 8 May 2017. The last patient visit was on 22 December 2017, with final database release on 16 January 2018.

In total, 719 patients were assigned to PF-06439535 plus paclitaxel and carboplatin (PF-06439535 group; 358 patients) or bevacizumab-EU plus paclitaxel and carboplatin (bevacizumab-EU group; 361 patients) and comprised the ITT population (Fig. 1). Of these, 714 patients received at least one dose of study drug or chemotherapy and were included in the safety population (356 patients in the PF-06439535 group and 358 patients in the bevacizumab-EU group).

Overall, the disposition of patients between treatment groups was comparable. Among the 714 patients in the safety population, the primary reason for discontinuation of PF-06439535 or bevacizumab-EU was objective disease progression or relapse (176 [49.4%] patients in the PF-06439535 group and 207 [57.8%] patients in the bevacizumab-EU group) (ESM, Table S2). Including the survival follow-up period, the most frequent reason for discontinuation from the study was death (136 [38.2%] patients in the PF-06439535 group and 138 [38.5%] patients in the bevacizumab-EU group).

Demographic and baseline characteristics of the ITT population were similar between the treatment groups (Table 1). Of the 719 randomized patients, 467 (65.0%) were male. The median age was 61.0 years, and more than half of patients (58.4%) were 45–64 years of age. The majority of patients were White (638 [88.7%] patients) or Asian (76 [10.6%] patients). In total, 547 (76.1%) patients had newly diagnosed Stage IV disease, while 95 (13.2%) patients presented at screening with recurrent disease. Overall, 129 (17.9%) patients had received prior resection of primary disease (not including biopsies), 35 (4.9%) had received prior systemic therapy, and 47 (6.5%) had received prior radiation therapy.

3.2 Treatment Exposure

As of study completion (22 December 2017), the extent of exposure was similar between treatment groups in the safety population. The mean (standard deviation) duration of treatment was 35.2 (27.19) weeks in the PF-06439535 group and 34.9 (25.96) weeks in the bevacizumab-EU group. In the PF-06439535 group, the median number of cycles of PF-06439535 treatment was 11.0 (range 1–41), with 6.0 cycles (range 1–6 cycles) of paclitaxel treatment and 6.0 cycles (range 1–6 cycles) of carboplatin treatment. In the bevacizumab-EU group, the median number of cycles of bevacizumab-EU treatment was 11.0 (range 1–38), with 6.0 cycles (range 1–6 cycles) of paclitaxel treatment and 6.0 cycles (range 1–6 cycles) of carboplatin treatment.

3.3 Primary Efficacy Endpoint

At the time of the data cutoff for the primary efficacy ORR analysis (8 May 2017), all randomized patients had completed the week 25 visit or had discontinued from the disease evaluation period earlier. In the ITT population, 45.3% (95% CI 40.01–50.57) of patients in the PF-06439535 group and 44.6% (95% CI 39.40–49.89) of patients in the bevacizumab-EU group achieved an objective response by week 19 that was confirmed by week 25 (Table 2). The unstratified ORR risk ratio was 1.015, with a 95% CI of 0.863–1.193 and a 90% CI of 0.886–1.163. The unstratified ORR risk difference was 0.653%, with a 95% CI of −6.608% to 7.908%. All three CIs fell entirely within the equivalence margins described earlier (Fig. 2). Thus, similarity between PF-06439535 and bevacizumab-EU was demonstrated for ORR, based on the pre-specified criteria for each of the three health authorities.

A sensitivity analysis based on the unstratified ORR risk ratio and risk difference in the PP population yielded results.
consistent with those in the ITT population (data cutoff date 8 May 2017; data not shown). Additional supportive results were obtained in ORR analyses adjusted for stratification factors, in both the ITT and PP populations (data cutoff date 8 May 2017; data not shown).

3.4 Secondary Efficacy Endpoints

Analyses of PFS, OS, and DOR were based on final data after study completion on 22 December 2017. In the ITT population, there were 228 (63.7%) patients in the PF-06439535 group and 255 (70.6%) patients in the

---

**Fig. 1** Participant flow diagram. aOne patient received paclitaxel and carboplatin but withdrew before receiving PF-06439535. bPatient was indicated as “study terminated by sponsor” by the investigator; however, this patient was considered to have met the definition of study completion (i.e. patient was alive and had completed survival follow-up as defined by the protocol). cThe most frequently reported reason for patients not being included in the PP population was due to being randomized but never dosed with PF-06439535 or bevacizumab-EU (3 [0.8%] patients in the PF-06439535 group and 3 [0.8%] patients in the bevacizumab-EU group). Bevacizumab-EU reference bevacizumab sourced from the European Union, COPD chronic obstructive pulmonary disease, ITT intent-to-treat, ORR objective response rate, PK pharmacokinetics, PP per-protocol.

Δ Adis
|                                | PF-06439535 group (N = 358) | Bevacizumab-EU group (N = 361) |
|--------------------------------|-----------------------------|------------------------------|
| **Sex**                        |                             |                              |
| Male                           | 237 (66.2)                  | 230 (63.7)                   |
| Female                         | 121 (33.8)                  | 131 (36.3)                   |
| **Age**                        |                             |                              |
| < 18 years                     | 0                           | 0                            |
| 18–44 years                    | 19 (5.3)                    | 17 (4.7)                     |
| 45–64 years                    | 198 (55.3)                  | 222 (61.5)                   |
| ≥ 65 years                     | 141 (39.4)                  | 122 (33.8)                   |
| Median (range), years          | 62.0 (25–87)                | 61.0 (31–83)                 |
| **Race**                       |                             |                              |
| White                          | 319 (89.1)                  | 319 (88.4)                   |
| Black                          | 3 (0.8)                     | 1 (0.3)                      |
| Asian                          | 36 (10.1)                   | 40 (11.1)                    |
| Other                          | 0                           | 1 (0.3)                      |
| **Childbearing potential**     |                             |                              |
| Yes                            | 212 (59.2)                  | 197 (54.6)                   |
| No                             | 146 (40.8)                  | 163 (45.2)                   |
| Not reported                   | 0                           | 1 (0.3)                      |
| **Smoking status**             |                             |                              |
| Never smoked                   | 103 (28.8)                  | 109 (30.2)                   |
| Smoker                         | 127 (35.5)                  | 117 (32.4)                   |
| Ex-smoker                      | 128 (35.8)                  | 135 (37.4)                   |
| **Histopathological classification** |                         |                              |
| Mixed adenocarcinoma           | 3 (0.8)                     | 4 (1.1)                      |
| Adenocarcinoma                 | 348 (97.2)                  | 351 (97.2)                   |
| Large cell carcinoma           | 6 (1.7)                     | 5 (1.4)                      |
| Other                          | 1 (0.3)                     | 1 (0.3)                      |
| **Recurrence type**            |                             |                              |
| Newly diagnosed Stage IIIB     | 48 (13.4)                   | 29 (8.0)                     |
| Newly diagnosed Stage IV       | 265 (74.0)                  | 282 (78.1)                   |
| Recurrent<sup>a</sup>          | 45 (12.6)                   | 50 (13.9)                    |
| **Time since initial diagnosis of NSCLC** |                     |                              |
| Median (range), months         | 1.2 (0.2–210.9)             | 1.3 (0.1–137.9)              |
| Missing/not reported           | 3 (0.8)                     | 3 (0.8)                      |
| **Screening ECOG performance status** |                       |                              |
| 0                              | 105 (29.3)                  | 122 (33.8)                   |
| 1                              | 252 (70.4)                  | 239 (66.2)                   |
| Missing/not reported           | 1 (0.3)                     | 0                            |
| **Prior surgeries<sup>b</sup> for primary diagnoses** |               |                              |
| No                             | 297 (83.0)                  | 293 (81.2)                   |
| Yes                            | 61 (17.0)                   | 68 (18.8)                    |
| **Prior systemic therapies for primary diagnoses** |             |                              |
| No                             | 343 (95.8)                  | 341 (94.5)                   |
| Yes                            | 15 (4.2)                    | 20 (5.5)                     |
| **Prior radiation therapies for primary diagnoses** |               |                              |
| No                             | 333 (93.0)                  | 338 (93.6)                   |
| Yes                            | 24 (6.7)                    | 23 (6.4)                     |
| Not reported                   | 1 (0.3)                     | 0                            |

<sup>a</sup> Adis
bevacizumab-EU group who had objective progression or died without objective progression. The estimated probability of being progression-free at 1 year was 33.1% (95% CI 27.6–38.6) in the PF-06439535 group and 30.9% (95% CI 25.7–36.1) in the bevacizumab-EU group (stratified HR 0.930, 95% CI 0.776–1.114; \( p = 0.4388 \)) (Fig. 3a). Overall, 144 (40.2%) patients in the PF-06439535 group and 149 (41.3%) patients in the bevacizumab-EU group died. The estimated probability of being alive at 1 year was 68.0% (95% CI 62.7–72.6) in the PF-06439535 group and 66.3% (95% CI 61.0–71.1) in the bevacizumab-EU group (stratified HR 0.918, 95% CI 0.729–1.157; \( p = 0.4726 \)) (Fig. 3b).

Among the 323 patients in the ITT population who achieved an objective response by week 19 that was confirmed by week 25, the estimated probability of maintaining response for 1 year was 33.8% (95% CI 25.9–41.9) in the PF-06439535 group and 30.8% (95% CI 23.3–38.6) in the bevacizumab-EU group (stratified HR 0.790, 95% CI 0.600–1.039; \( p = 0.0906 \)). The estimated median DOR was 8.3 months (95% CI 7.3–10.0) in the PF-06439535 group and 6.6 months (95% CI 6.2–8.3) in the bevacizumab-EU group.

### 3.5 Safety

Safety analyses were performed on final data (22 December 2017). In the safety population, 344 (96.6%) patients in the PF-06439535 group and 347 (96.9%) patients in the bevacizumab-EU group were included.

---

**Table 2** Summary of best overall response and ORR based on responses achieved by week 19 and confirmed by week 25 (intent-to-treat population)

| Best overall response, n (%) | PF-06439535 group (\( N = 358 \)) | Bevacizumab-EU group (\( N = 361 \)) |
|-----------------------------|-----------------------------------|---------------------------------------|
| Complete response (CR)      | 9 (2.5)                           | 4 (1.1)                               |
| Partial response (PR)       | 153 (42.7)                        | 157 (43.5)                            |
| Stable disease              | 154 (43.0)                        | 166 (46.0)                            |
| Objective progression       | 15 (4.2)                          | 14 (3.9)                              |
| Indeterminate\(^a\)         | 27 (7.5)                          | 20 (5.5)                              |
| ORR (CR + PR), n (%)        | 162 (45.3)                        | 161 (44.6)                            |
| 95% exact CI\(^b\), %       | 40.01–50.57                       | 39.40–49.89                           |

Treatment comparison (vs bevacizumab-EU group)

| Unstratified ORR risk difference\(^c\), % | 0.653 |
| 95% CI of difference\(^c\), %          | 0.653–0.806 |

Treatment comparison (vs bevacizumab-EU group)

| Unstratified ORR risk ratio\(^c\) | 1.015 |
| 95% CI of risk ratio\(^c\)        | 0.863–1.193 |
| 90% CI of risk ratio\(^c\)        | 0.886–1.163 |

Data cutoff date 8 May 2017. ORR defined as the percentage of patients within each treatment group who achieved complete response or partial response by week 19 of the study in accordance with RECIST version 1.1, which was subsequently confirmed by week 25.

\(^a\)Indeterminate: early death, unevaluable tumor assessment, and early study discontinuations

\(^b\)Exact method based on F-distribution was used

\(^c\)Based on 2-sided Miettinen and Nurminen method without stratification variables
bevacizumab-EU group experienced at least one TEAE (Table 3). The most frequently reported all-causality TEAEs were alopecia (166 [46.6%] patients in the PF-06439535 group vs 165 [46.1%] patients in the bevacizumab-EU group) and anemia (104 [29.2%] patients vs 108 [30.2%] patients).

There were 171 (48.0%) patients in the PF-06439535 group and 172 (48.0%) patients in the bevacizumab-EU group with a TEAE reported at grade 3 or higher. The most frequently reported grade 3 or higher TEAEs were hypertension, neutropenia, and anemia (Table 3). Deaths that occurred during the treatment period and up to 28 days after the last dose of study drug were considered grade 5 TEAEs. The incidence of grade 5 TEAEs was similar between the two treatment groups (Table 3). Regarding grade 5 TEAEs related to PF-06439535 or bevacizumab-EU, there were six events in the PF-06439535 group and one event in the bevacizumab-EU group. Three of the six deaths (acute myocardial infarction, pneumonia, and pulmonary hemorrhage) in the PF-06439535 group were considered to be also related to paclitaxel and carboplatin. Grade 5 TEAEs related to PF-06439535 or bevacizumab-EU were consistent with the complications of underlying disease and the known safety profile of reference bevacizumab [5, 6].
Fig. 3 Kaplan–Meier plots of a progression-free survival and b overall survival in the intent-to-treat population. Final data after study completion on 22 December 2017. a CI based on product-limit method. b CI based on Brookmeyer and Crowley method. c Hazard ratio based on Cox proportional hazards model stratified by region, sex, and smoking history. d Two-sided p-value based on log-rank test stratified by region, sex, and smoking history. Bevacizumab-EU reference bevacizumab sourced from the European Union. CI confidence interval, NE not estimable.
Serious TEAEs were experienced by 81 (22.8%) patients in the PF-06439535 group and 80 (22.3%) patients in the bevacizumab-EU group. The most frequently reported serious TEAEs were pneumonia, febrile neutropenia, and neutropenia, which occurred at a similar incidence between the treatment groups (Table 3).

No clinically meaningful differences in the incidence of any TEAEs of special interest were identified between the groups (ESM, Table S3). The most frequently reported grade 3 or higher TEAE of special interest was hypertension (34 [9.6%] patients in the PF-06439535 group and 32 [8.9%] patients in the bevacizumab-EU group) (Table 3).

There were no notable differences between the groups in laboratory results, maximal post-baseline shifts in blood pressure, absolute declines in left ventricular ejection fraction, or electrocardiograms.

Table 3  Summary of TEAEs of all causalities (safety population)

|                                 | PF-06439535 group (N = 356) | Bevacizumab-EU group (N = 358) |
|---------------------------------|-----------------------------|---------------------------------|
| **Number of TEAEs**            | 2442                        | 2470                            |
| **TEAEs**                       |                             |                                 |
| Any                             | 344 (96.6)                  | 347 (96.9)                      |
| Serious                         | 81 (22.8)                   | 80 (22.3)                       |
| Grade 3                         | 125 (35.1)                  | 104 (29.1)                      |
| Grade 4                         | 25 (7.0)                    | 44 (12.3)                       |
| Grade 5                         | 21 (5.9)                    | 24 (6.7)                        |
| Led to discontinuation of any treatment | 85 (23.9)                  | 86 (24.0)                       |
| **Grade 3 or higher TEAEs by preferred term in ≥5% of patients in either treatment group**a |                             |                                 |
| Hypertension                    | 33 (9.3)                    | 31 (8.7)                        |
| Neutropenia                     | 26 (7.3)                    | 32 (8.9)                        |
| Anemia                          | 19 (5.3)                    | 18 (5.0)                        |
| **Grade 3 or higher TEAEs of special interest by category** |                             |                                 |
| Arterial thromboembolic events  | 6 (1.7)                     | 6 (1.7)                         |
| Bleeding/hemorrhage (including pulmonary hemorrhage) | 8 (2.2)                     | 7 (2.0)                         |
| Cardiac disorders               | 10 (2.8)                    | 12 (3.4)                        |
| Congestive heart failure        | 1 (0.3)                     | 3 (0.8)                         |
| Gastrointestinal perforation    | 0                           | 2 (0.6)                         |
| Hypertension, only grade 3 or higher | 34 (9.6)                  | 32 (8.9)                        |
| Proteinuria/nephrotic syndrome  | 4 (1.1)                     | 5 (1.4)                         |
| Venous thromboembolic events    | 8 (2.2)                     | 4 (1.1)                         |
| **Serious TEAEs by preferred term in ≥1% of patients in either treatment group**a |                             |                                 |
| Pneumonia                       | 8 (2.2)                     | 6 (1.7)                         |
| Febrile neutropenia             | 5 (1.4)                     | 7 (2.0)                         |
| Neutropenia                     | 4 (1.1)                     | 6 (1.7)                         |
| Disease progression             | 4 (1.1)                     | 5 (1.4)                         |
| Pulmonary embolism              | 7 (2.0)                     | 2 (0.6)                         |
| Anemia                          | 2 (0.6)                     | 5 (1.4)                         |
| Asthenia                        | 4 (1.1)                     | 1 (0.3)                         |
| Gastroenteritis                 | 4 (1.1)                     | 0                               |
| Hyponatremia                    | 4 (1.1)                     | 0                               |

Data are presented as number (%) of patients unless otherwise specified. Final data after study completion on 22 December 2017. Data collected up to 28 days after the last dose of study drug or to start of subsequent anticancer therapy, whichever came first. Except for the number of TEAEs, patients were counted only once per treatment in each row. Serious adverse events were determined according to the investigator’s assessment. Severity counts were based on the maximum severity or grade of events.

*Bevacizumab-EU* reference bevacizumab sourced from the European Union, *N* number of patients evaluable for adverse events, *TEAE* treatment-emergent adverse event

*aMedical Dictionary for Regulatory Activities version 20.1 coding dictionary applied*
3.6 PK and Immunogenicity

PK and immunogenicity analyses were conducted on final data (22 December 2017). In the PK population, mean serum concentrations were generally comparable between the two treatment groups at all time points measured from baseline through cycle 18, day 1 (Fig. 4). No comparison of summary statistics of serum concentrations between the two groups after this time point was conducted, because such comparison was considered to be substantially confounded by the limited number of patients at the later time points.

The observed rate of immunogenicity in the safety population was low, with comparable percentages of patients with ADAs and NAbs observed for the two groups. In the overall post-treatment assessment, five (1.5%) of 339 patients in the PF-06439535 group and five (1.4%) of 350 patients in the bevacizumab-EU group were reported ADA-positive (Table 4). This included one patient in the bevacizumab-EU group who was also ADA-positive at baseline. All nine patients with treatment-emergent ADAs (five in the PF-06439535 group and four in the bevacizumab-EU group) had low titers, and the treatment-emergent ADAs appeared to be transient. In the overall post-treatment assessment, of the five patients who reported positive ADA status in the PF-06439535 group, none was NAb-positive; of the five patients who reported positive ADA status in the bevacizumab-EU group, three (0.9%) were NAb-positive (data for baseline NAb incidence not shown). Given the low number of patients with ADAs, the association between immunogenicity and safety could not be evaluated. No apparent impact of the low-titer ADAs on PK was observed.

Fig. 4 Mean serum concentrations of PF-06439535 and bevacizumab-EU in the PK population. Final data after study completion on 22 December 2017. Triangle or square and bar represent the mean with standard deviation. Concentrations are pre-dose (0-h time point) unless otherwise noted. Summary statistics calculated by setting concentration values below the LLOQ (< 250 ng/mL) to 0. Unplanned readings excluded. Samples with a time deviation of >20% or any positive time deviation from the 0-h planned time point excluded. End of treatment and early withdrawal samples excluded. Standard deviation not shown for the 0-h time point at cycle 1, day 1 because the bars would be shorter than the height of the triangle and square symbols. There were 20 patients in the PF-06439535 group and 17 patients in the bevacizumab-EU group with measurable pre-dose concentrations above the LLOQ on cycle 1, day 1. Patients with measurable pre-dose concentrations >5% of apparent $C_{\text{max}}$ (serum concentration at 2.5-h time point) on cycle 1, day 1 were included from the summary analysis. After this pre-specified exclusion, six patients in the PF-06439535 group and seven patients in the bevacizumab-EU group with measurable pre-dose concentrations on cycle 1, day 1 were included in the summary. Bevacizumab-EU reference bevacizumab sourced from the European Union, $C$ cycle, $C_{\text{max}}$ maximum concentration, h hour(s), LLOQ lower limit of quantification, PK pharmacokinetics.
4 Discussion

Based on pre-specified equivalence margins agreed with the FDA, EMA, and PMDA, this study demonstrated similarity between PF-06439535 and bevacizumab-EU in terms of ORR, when each treatment was combined with paclitaxel and carboplatin in the first-line treatment of advanced non-squamous NSCLC. There were no clinically meaningful differences observed between groups for secondary efficacy endpoints, safety, PK, or immunogenicity, as expected. Furthermore, no new safety signals were identified in the PF-06439535 group compared with the established safety profile of reference bevacizumab. The observation that serum concentrations of PF-06439535 and bevacizumab-EU were generally similar between the two groups at multiple time points supports the findings from the previous single-dose study that established PK similarity between PF-06439535, bevacizumab-EU, and bevacizumab-US in healthy male volunteers [21].

Our study was designed in accordance with guidance on demonstrating biosimilarity from the FDA and the EMA [14, 28], in conjunction with scientific advice from regulatory authorities. Although survival-based endpoints are important when seeking to establish clinical benefit for a novel anticancer agent, such endpoints are less suitable for demonstrating biosimilarity [29]. Whereas PFS and OS may be influenced by factors such as tumor burden and subsequent lines of therapy, ORR is a direct measure of drug antitumor activity and hence is considered a sensitive endpoint for detecting potential product-related differences between a biosimilar and reference product [29, 30]. Indeed, ORR has been used as the primary endpoint in comparative clinical studies of other oncology biosimilars [31–34]. Additionally, bevacizumab plus paclitaxel and carboplatin has a well-characterized safety and efficacy profile as first-line therapy for patients with advanced non-squamous NSCLC [8]. Considering these factors, the design of the current study was considered sufficiently sensitive for detecting any clinically meaningful differences between PF-06439535 and bevacizumab-EU, should they exist.

This study incorporated design features from historical trials of reference bevacizumab plus paclitaxel and carboplatin [8, 26, 27], and patient eligibility criteria were similar to those in a pivotal phase III study of reference bevacizumab in NSCLC (ECOG 4599) [8]. Although cross-trial comparisons should be made with caution, ORR in the ECOG 4599 arm treated with reference bevacizumab plus paclitaxel and carboplatin was 35%, and was therefore similar to the response rates observed in the current study (45.3% in the PF-06439535 group and 44.6% in the bevacizumab-EU group). Notably, median OS in the ECOG 4599 study arm treated with reference bevacizumab plus paclitaxel and carboplatin was shorter than that observed in both arms in our study, at 12.3 months as compared with 19.4 months (PF-06439535 group) and 17.8 months (bevacizumab-EU group) [8]. Certain advances since the conduct of the historical trial may have contributed to these differences; for example, patients in the current study were able to receive follow-up anticancer therapy with treatments that were not available at the time of the ECOG 4599 study, including pemetrexed and immune-checkpoint inhibitors such as nivolumab [35, 36].

One potential limitation of our study was that patient recruitment was weighted towards a minority of the 27 enrolling countries. Ten countries (Russia, Ukraine, Romania, Hungary, Poland, Germany, Turkey, India, Japan, and Greece) accounted for 85.4% of the total enrollment, with 45.6% of the overall study population recruited from centers in Russia and Ukraine only. Additionally, subsequent

| Table 4 | Summary of ADA incidence (safety population) |
|----------------|---------------------------------------------|
| Visit Criteria | PF-06439535 group (N = 356) | Bevacizumab-EU group (N = 358) |
| Cycle 1 (prior to treatment) | Number of patients evaluated | 352 | 353 |
| | Positive | 1 (0.3) | 3 (0.8) |
| | Negative | 350 (99.4) | 350 (99.2) |
| | Not tested | 1 (0.3) | 0 |
| Overall (post-treatment) | Number of patients evaluated | 339 | 350 |
| | Positive | 5 (1.5) | 5 (1.4) |
| | Negative | 334 (98.5) | 345 (98.6) |

Data are presented as number (%) of patients unless otherwise specified. Final data after study completion on 22 December 2017. Percentages based on the number of patients evaluated at each visit. All samples taken prior to dosing. ADA-positive sample defined as ADA titer ≥ 2.29, ADA-negative sample defined as ADA titer < 2.29.

ADA anti-drug antibody, bevacizumab-EU reference bevacizumab sourced from the European Union, N number of patients who received study drug.

*For calculation of the overall incidence of post-treatment ADA, the denominator was the number of patients with at least one post-cycle 1 ADA sample tested. Patients with a positive ADA sample at any time post-cycle 1 were defined as having an overall positive ADA status.*
lines of treatment might have been affected by drug availability discrepancies across different countries. However, as the proportions of patients enrolled from each country were well balanced between the treatment groups, the comparison of PF-06439535 and bevacizumab-EU was not adversely affected. Of note, high rates of recruitment from Russia and countries in Eastern Europe have been observed in other recent comparative clinical studies of oncology biosimilars [32, 37, 38].

With respect to the applicability of the results to current practice, it is noteworthy that bevacizumab added to a platinum-based chemotherapy doublet remains a first-line option in the treatment of advanced or metastatic non-squamous NSCLC negative for molecular testing [10, 11]. However, the recent introduction of immune-checkpoint inhibitors has led to an expanded range of available first-line therapeutic options [11]. In this new era, we anticipate that bevacizumab may have an important role when used in combination with immunotherapy. Results from the IMPower150 trial, for example, showed that the addition of atezolizumab to bevacizumab plus carboplatin and paclitaxel in the first-line treatment of non-squamous metastatic NSCLC led to a significant improvement in both PFS and OS, with the PFS benefit observed in key clinical and biomarker subgroups [39].

Addressing escalating healthcare costs and improving patient access to treatment remain priorities in the treatment of cancer, and biosimilars are expected to have a key role [17, 18]. In addition to PF-06439535, several potential bevacizumab biosimilars are in clinical development, and in most instances confirmatory clinical studies have been conducted in patients with advanced non-squamous NSCLC [31, 40]. Furthermore, the bevacizumab biosimilar ABP 215 has been licensed in the US and authorized in the EU [41, 42].

5 Conclusions

In conclusion, this study in patients with advanced non-squamous NSCLC demonstrated similarity between PF-06439535 and bevacizumab-EU in terms of the primary efficacy endpoint of ORR, when each was administered in combination with paclitaxel and carboplatin as first-line treatment. No notable differences were observed between the groups in PFS or OS. There were no clinically meaningful differences in safety profile, and similar PK and immunogenicity results were observed across treatment groups. These results confirm the similarity demonstrated in earlier analytical, nonclinical, and clinical studies of PF-06439535 and reference bevacizumab [20, 21].

Acknowledgements We would like to thank the patients, caregivers, and investigators who contributed to the B7391003 study. Medical writing support was provided by Paul Shepherd, MA, CMPP of Engage Scientific Solutions and was funded by Pfizer.

Author Contributions All authors contributed to the acquisition, analysis, or interpretation of data, and to drafting or revising the manuscript. All authors approved the final version of the manuscript and agree to be accountable for all aspects of the work. Niels Reinmuth is guarantor for the overall content.

Compliance with Ethical Standards

Funding This study was sponsored by Pfizer. Pfizer representatives were involved in the design and conduct of the study, data analysis, and manuscript preparation (see ‘Author contributions’ statement). Open access publication of this article was funded by Pfizer.

Conflict of interest Niels Reinmuth has received consulting fees or honoraria from Hoffmann-La Roche, Lilly, Boehringer Ingelheim, Novartis, AstraZeneca, MSD, Celgene, Takeda, and Bristol-Myers Squibb, support for travel from Hoffmann-La Roche, Boehringer Ingelheim, AstraZeneca, Takeda, and Bristol-Myers Squibb, and fees for participation in review activities from Merck. Maciej Bryl has received consulting fees or honoraria from Boehringer Ingelheim, Novartis, AstraZeneca, MSD, and Bristol-Myers Squibb, support for travel from Hoffmann-La Roche/Genentech, Boehringer Ingelheim, MSD, Bristol-Myers Squibb, Pfizer, and AstraZeneca, and payments for lectures from Roche/Genentech, Boehringer Ingelheim, MSD, Bristol-Myers Squibb, Pfizer, and AstraZeneca. Angel H. Bair, Fiona Hilton, and Katherine Lian are employees of and hold stock or stock options in Pfizer. Kazuo Kasahara has received honoraria from Pfizer, Chugai Pharmaceutical, MSD, Bristol-Myers Squibb, and AstraZeneca. Costas Syrigos has received honoraria and consulting fees from AstraZeneca, MSD, Roche, and Bristol-Myers Squibb. Angel H. Bair, Fiona Hilton, and Katherine Lian are employees of and hold stock or stock options in Pfizer. Kazuo Kasahara has received honoraria from Pfizer, Chugai Pharmaceutical, MSD, AstraZeneca, Bristol-Myers Squibb, and IQVIA. Igor Bondarenko, Vladimir Vladimirov, and Manuela Zereu disclose no conflicts of interest.

Ethical approval This study was conducted in compliance with the ethical principles originating in or derived from the Declaration of Helsinki and in compliance with all International Council for Harmonisation Good Clinical Practice Guidelines. In addition, all local regulatory requirements were followed. The final protocol, any amendments, and informed consent documentation were reviewed and approved by the institutional review boards and/or independent ethics committees at each of the investigational centers participating in the study.

Informed consent A signed and dated informed consent document was required from each patient before any screening procedures were done.

Data availability Upon request, and subject to certain criteria, conditions, and exceptions (see https://www.pfizer.com/science/clinical-trials/trial-data-and-results for more information), Pfizer will provide access to individual de-identified participant data from Pfizer-sponsored global interventional clinical studies conducted for medicines, vaccines, and medical devices (1) for indications that have been approved in the US and/or EU or (2) in programs that have been terminated (i.e., development for all indications has been discontinued). Pfizer will also consider requests for the protocol, data dictionary, and statistical analysis plan. Data may be requested from Pfizer trials 24 months after study completion. The de-identified participant data will be made available to researchers whose proposals meet the research criteria and other conditions, and for which an exception does not apply, via a secure portal. To gain access, data requestors must enter into a data access agreement with Pfizer.
Open Access
This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References
1. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9:669–76. https://doi.org/10.1038/nm0603-669.
2. Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol. 2002;20:4368–80. https://doi.org/10.1200/JCO.2002.10.088.
3. Ferrara N. Vascular endothelial growth factor as a target for anti-cancer therapy. Oncologist. 2004;9(Suppl 1):2–10.
4. Toi M, Matsumoto T, Bando H. Vascular endothelial growth factor: its prognostic, predictive, and therapeutic implications. Lancet Oncol. 2001;2:667–73. https://doi.org/10.1016/s1470-2045(01)00556-3.
5. Genentech Inc. Avastin prescribing information. 2018 (last update June 2018). https://www.accessdata.fda.gov/drugsatfda_docslabel/2018/125085s323lbl.pdf. Accessed 30 Apr 2019.
6. Roche Registration GmbH. Summary of product characteristics: Avastin. 2018 (last update 31 August 2018). https://www.ema.europa.eu/documents/product-information/avastin-epar-product-information_en.pdf. Accessed 30 Apr 2019.
7. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335–42. https://doi.org/10.1056/nejmoa032691.
8. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355:2542–50. https://doi.org/10.1056/nejmoa061884.
9. Tewari KS, Sill MW, Long HJ 3rd, Penson RT, Huang H, Ramondetta LM, et al. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med. 2014;370:734–43. https://doi.org/10.1056/nejmoa130748.
10. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Non-small cell lung cancer. Version 4-2019. 2019 (last update 29 April 2019). https://www.nccn.org/professionals/physician_gls/pdf/nsccl.pdf. Accessed 30 Apr 2019.
11. Planchard D, Popat S, Kerr K, Novello S, Smit EF, Faivre-Finn C, et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29:iv192–237. https://doi.org/10.1093/annonc/mdy275.
12. Monk BJ, Lammers PE, Cartwright T, Jacobs I. Barriers to the access of bevacizumab in patients with solid tumors and the potential impact of biosimilars: a physician survey. PharmacoEconomics (Basel). 2017;10:19. https://doi.org/10.3390/pharmaco10010019.
13. European Medicines Agency. Guideline on similar biological medicinal products. 2014 (last update 23 October 2014). https://www.ema.europa.eu/documents/scientific-guideline/guideline-similar-biological-medicinal-products-rev1_en.pdf. Accessed 30 Apr 2019.
14. US Food and Drug Administration. Scientific considerations in demonstrating biosimilarity to a reference product: guidance for industry. 2015 (last update April 2015). https://www.fda.gov/media/82647/download. Accessed 9 May 2019.
15. World Health Organization. Guidelines on evaluation of similar biotherapeutic products (SBPs). 2009 (last update 23 October 2009). http://www.who.int/biologicals/areas/biological_therapeutics/BIOThERAPUTICS_FOR_WEB_22APRIL2010.pdf. Accessed 30 Apr 2019.
16. QuintilesIMS. The impact of biosimilar competition in Europe. 2017 (last update 5 May 2017). https://ec.europa.eu/docsroom/documents/23102/attachments/1/translations/en renditions/pdf. Accessed 30 Apr 2019.
17. Lyman GH, Balaban E, Diaz M, Ferris A, Tsao A, Voest E, et al. American Society of Clinical Oncology Statement: biosimilars in oncology. J Clin Oncol. 2018;36:1260–5. https://doi.org/10.1200/JCO.2017.77.4893.
18. Tabernero J, Vyas M, Giuliani R, Arnold D, Cardoso F, Casali PG, et al. Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers. ESMO Open. 2016;1:e000142. https://doi.org/10.1136/esmoopen-2016-000142.
19. Pfizer Europe MA EElG. Zirabev summary of product characteristics. 2019 (last update 16 April 2019). https://www.ema.europa.eu/en/documents/product-information/zirabev-epar-product-information_en.pdf. Accessed 7 May 2019.
20. Peraza MA, Rule KE, Shiuie MH, Finch GL, Thibault S, Brown PR, et al. Nonclinical assessments of the potential biosimilar PF-06439535 and bevacizumab. Regul Toxicol Pharmacol. 2018;95:236–43. https://doi.org/10.1016/j.yrtph.2018.03.020.
21. Knight B, Rassam D, Liao S, Esvesuedo R. A phase I pharmacokinetics study comparing PF-06439535 (a potential biosimilar) with bevacizumab in healthy male volunteers. Cancer Chemother Pharmacol. 2016;77:839–46. https://doi.org/10.1007/s00028-016-3001-2.
22. Edge SB. American Joint Committee on Cancer. AJCC cancer staging manual. 7th ed. New York: Springer; 2010.
23. Goldstraw P, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol. 2007;2:706–14. https://doi.org/10.1097/jto.0b013e318121e3c1.
24. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47. https://doi.org/10.1016/j.ejca.2008.10.026.
25. Miettinen O, Nurminen M. Comparative analysis of two rates. Stat Med. 1985;4:213–26.
26. Niho S, Kunitoh H, Nokihara H, Horai T, Ichinose Y, Hida T, et al. Randomized phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced nonsquamous non-small-cell lung cancer. Lung Cancer. 2012;76:362–7. https://doi.org/10.1016/j.lungcan.2011.12.005.
27. Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2004;22:2184–91. https://doi.org/10.1200/JCO.2004.11.022.
28. European Medicines Agency. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. 2014 (last update 18 December 2014). https://www.ema.europa.eu/documents/scientific-guideline/guideline-similar-biological-medicinal-products-containing-biotechnology-derived-proteins-active_en-2.pdf. Accessed 30 Apr 2019.
29. European Medicines Agency. Guideline on similar biological medicinal products containing monoclonal antibodies—non-clinical and clinical issues. 2012 (last update 30 May 2012). https://www.ema.europa.eu/documents/scientific-guideline/guideline-similar-biological-medicinal-products-containing-monoclonal-antibodies-non-clinical_en.pdf. Accessed 30 Apr 2019.

30. US Food and Drug Administration. Guidance for Industry. Clinical trial endpoints for the approval of cancer drugs and biologics. 2018 (last update December 2018). https://www.fda.gov/media/71195/download. Accessed 30 Apr 2019.

31. Thatcher N, Goldschmidt JH, Thomas M, Schenker M, Pan Z, Paz-Ares Rodriguez L, et al. Efficacy and safety of the biosimilar ABP 215 compared with bevacizumab in patients with advanced nonsquamous non-small cell lung cancer (MAPLE): a randomized, double-blind, phase III study. Clin Cancer Res. 2019;25:2088–95. https://doi.org/10.1158/1078-0432.ccr-18-2702.

32. Rugo HS, Barve A, Waller CF, Hernandez-Bronchud M, Herson J, Yuan J, et al. Effect of a proposed trastuzumab biosimilar compared with trastuzumab on overall response rate in patients with ERBB2 (HER2)-positive metastatic breast cancer: a randomised, double-blind, phase III trial. Lancet Oncol. 2018;19:917–28. https://doi.org/10.1016/s1470-2045(17)30434-5.

33. Jurczak W, Moreira I, Kanakasetty GB, Munhoz E, Echeveste MA, Giri P, et al. Rituximab biosimilar and reference rituximab in patients with previously untreated advanced follicular lymphoma (ASSIST-FL): primary results from a confirmatory phase 3, double-blind, randomised, controlled study. Lancet Haematol. 2017;4:e350–61. https://doi.org/10.1016/s2352-3026(17)30106-0.

34. Ogura M, Sancho JM, Cho SG, Nakazawa H, Suzumiya J, Timyan G, et al. Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 in comparison with rituximab in patients with previously untreated low-tumour-burden follicular lymphoma: a randomised, double-blind, parallel-group, phase 3 trial. Lancet Haematol. 2018;5:e543–53. https://doi.org/10.1016/s2352-3026(18)30157-1.

35. Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004;22:1589–97. https://doi.org/10.1200/jco.2004.08.163.

36. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373:1627–39. https://doi.org/10.1056/nejmoa1507643.

37. Stebbing J, Baranau Y, Baryash V, Manikhas A, Moiseyenko V, Dzagnidze G, et al. CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial. Lancet Oncol. 2017;18:917–28. https://doi.org/10.1016/s1470-2045(17)30434-5.

38. von Minckwitz G, Colleoni M, Kolberg HC, Morales S, Santi P, Tomasevic Z, et al. Efficacy and safety of ABP 980 compared with reference trastuzumab in women with HER2-positive early breast cancer (LILAC study): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2018;19:987–98. https://doi.org/10.1016/s1470-2045(18)30241-9.

39. Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nomog N, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018;378:2288–301. https://doi.org/10.1016/j.amej.2017.11.025.

40. Rosen LS, Jacobs IA, Burkes RL. Bevacizumab in colorectal cancer: current role in treatment and the potential of biosimilars. Target Oncol. 2017;12:599–610. https://doi.org/10.1007/s11523-017-0518-1.

41. Amgen Inc. Mvasi (bevacizumab-awwb) prescribing information. 2017 (last update September 2017). https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761028s000lbl.pdf. Accessed 30 Apr 2019.

42. Amgen Europe B.V. Mvasi summary of product characteristics. 2018 (last update 10 April 2019). https://www.ema.europa.eu/documents/product-information/mvasi-epar-product-informatio n_en.pdf. Accessed 30 Apr 2019.

Affiliations

Niels Reinmuth1 · Maciej Bryl2 · Igor Bondarenko3 · Kostas Syrigos4 · Vladimir Vladimirov5 · Manuela Zereu6 · Angel H. Bair7 · Fiona Hilton7 · Katherine Liau7 · Kazuo Kasahara8

1 Department of Thoracic Oncology, Asklepios Lung Clinic Munich-Gauting, Robert-Koch-Allee 2, 82131 Gauting, Germany
2 Oncology Department, E.J. Zeyland Wielkopolska Center of Pulmonology and Thoracic Surgery, Poznan, Poland
3 Oncology and Medical Radiology Department, Dnipropetrovsk Medical Academy, Dnipro, Ukraine
4 3rd Department of Medicine, National and Kapodistrian University of Athens, Sotiria General Hospital, Athens, Greece
5 Outpatient Department, Pyatigorsk Oncology Dispensary, Pyatigorsk, Stavropol Region, Russian Federation
6 Nucleo de Oncologia, Santa Casa Hospital, Porto Alegre, Rio Grande Do Sul, Brazil
7 Pfizer, Groton, Connecticut, USA
8 Respiratory Medicine, Kanazawa University Hospital, Ishikawa, Japan

△ Adis